Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-096246
Filing Date
2024-08-13
Accepted
2024-08-13 16:16:21
Documents
65
Period of Report
2024-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q fnch-20240630.htm   iXBRL 10-Q 1152482
2 EX-31.1 fnch-ex31_1.htm EX-31.1 16901
3 EX-31.2 fnch-ex31_2.htm EX-31.2 17133
4 EX-32.1 fnch-ex32_1.htm EX-32.1 15413
  Complete submission text file 0000950170-24-096246.txt   5353573

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT fnch-20240630.xsd EX-101.SCH 941320
67 EXTRACTED XBRL INSTANCE DOCUMENT fnch-20240630_htm.xml XML 738646
Mailing Address 75 STATE STREET SUITE 100 BOSTON MA 02109
Business Address 75 STATE STREET SUITE 100 BOSTON MA 02109 617-229-6499
Finch Therapeutics Group, Inc. (Filer) CIK: 0001733257 (see all company filings)

EIN.: 823433558 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40227 | Film No.: 241201702
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)